- WuXi PharmaTech (WX +0.6%) announces a licensing agreement with Mayo Clinic's Center for Individualized Medicine.
- The deal gives WX an exclusive license to a "panel of patient-derived xenograft [mouse] models for prevailing cancers in Western countries."
- Ultimately, the goal here is to give WX a more extensive portfolio of models so that the company's customers can "select highly relevant models with a higher probability of success for testing targeted therapies." (PR)
WuXi PharmaTech inks licensing agreement with Mayo Clinic for PDX models
Nov 4 2013, 14:09 ET